Navigation Links
Heart Failure: Targeting the right patients for CRT-D
Date:5/22/2011

Patients with dyssynchronous yet viable ventricles are most likely to benefit from cardiac resynchronization therapy combined with defibrillation, concludes the latest analysis of the MADIT CRT trial. The CRT-MADIT-CRT trial - presented at the Heart Failure Congress 2011, organized by the Heart Failure Association of the European Society of Cardiology (ESC) in Late Breaking Session 1 - showed that CRT produced improvements in both synchrony and contractile function, and that the extent of this benefit relates to subsequent outcomes.

The Multicentre Automatic Defibrillator Implantation Trial-CRT (MADIT-CRT) set out to determine whether patients with mild heart failure (NYHA class I or II) would do better if they got implanted with a CRT-D device (which combines cardiac resynchronization therapy with defibrillation), than if they only received the traditional ICD defibrillation. In earlier studies CRT-D devices had been approved for use in patients with severe heart failure (NYHA class III/IV).

In the MADIT-CRT study, funded by Boston Scientific, 1820 patients with Class I and II heart failure, wide QRS and left ventricular dysfunction were randomized 3:2 to receive CRT-D (n=1089) or ICD alone (n=731). Results, presented at the 2009 ESC Annual Conference in Barcelona after a follow period averaging 2.4 years, demonstrated a greater than 40% reduction in the primary endpoint of death or heart failure in patients receiving CRT-D. However, in virtually all studies of CRT-D approximately 30% of patients do not respond to therapy.

In the current study, Dr Scott D Solomon (Brigham and Women's Hospital, Boston, MA) and colleagues set out to investigate whether the degree of synchrony the extent to which the walls of the left ventricle contract in unison might influence the likelihood of patients responding to CRT-D. "It's important to target patients in whom CRT-D works well because the technology is quite expensive," explained Solomon
'/>"/>

Contact: Jacqueline Partarrieu
press@escardio.org
33-492-947-756
European Society of Cardiology
Source:Eurekalert

Page: 1 2

Related biology news :

1. Dark chocolate: Half a bar per week to keep at bay the risk of heart attack
2. NIH awards Clemson bioengineer $1.5 million to improve durability of tissue heart valves
3. Researchers study how pistachios may improve heart health
4. Argonne scientists peer into heart of compound that may detect chemical, biological weapons
5. LIAI launches new division to look at novel approaches to heart disease and inflammation
6. Study provides insight on a common heart rhythm disorder
7. Embryonic heart exhibits impressive regenerative capacity
8. Repair in the developing heart
9. Drug-embedded microparticles bolster heart function in animal studies
10. Heart valves that grow with the patient
11. Research uncovers new steps on pathway to enlarged heart
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 15, 2014 Research and Markets ... addition of the "Samsung Galaxy S5 - ... report to their offering. ... totally different sensing technology than the iPhone 5S, ... sensor in its product. The Galaxy ...
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ... and robust – with the clinical data to back ...
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ... of the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition ... individuals. Facial recognition system measures the overall facial ... edges, mouth, and the distance between eyes. Facial ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... changes, might in fact be driven by a simple and ... range of specieshappen to share, according to new research. ... suggests that knowledge of a species, genes and how ... could be used to determine a predictable evolutionary pattern ...
... University of South Florida researchers have identified a genetic ... understanding and preventing a condition of aging that affects ... life. In a nine-year study that was a ... Research and the National Technical Institute for the Deaf ...
... 2012Targeted T-cells can seek out and destroy tumor cells ... that take advantage of this T-cell response are described ... a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. ... Gene Therapy website at http://www.liebertpub.com/hum . ...
Cached Biology News:Far from random, evolution follows a predictable genetic pattern, Princeton researchers find 2Far from random, evolution follows a predictable genetic pattern, Princeton researchers find 3Far from random, evolution follows a predictable genetic pattern, Princeton researchers find 4Far from random, evolution follows a predictable genetic pattern, Princeton researchers find 5USF researchers identify gene mutation linked to old age hearing loss 2New anti-tumor cell therapy strategies are more effective 2
(Date:12/24/2014)... 2014 On Friday, December 19, ... the Omnibus and Continuing Resolution Appropriations Act of ... a condition eligible to receive funding through the ... the Department of Defense (DoD). The Hydrocephalus Association ... Capitol Hill, is celebrating this victory for the ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 Pipette.com announces ... their Twitter followers can submit their #HolidayInTheLab pictures for ... their lab mates. , For those struggling to think ... the Pipette.com Holiday in the Lab Contest provides the ... Twitter followers to send pictures of their chemistree, ...
(Date:12/24/2014)... , Dec. 23, 2014  Rock Creek Pharmaceuticals, Inc., ... has filed a Clinical Trial Application (CTA) with the ... Regulatory Agency (MHRA) seeking regulatory approval to initiate clinical ... Anatabine Citrate. Contingent on the Company receiving ... Phase I trial to assess the safety, tolerability and ...
(Date:12/22/2014)... HILL, N.C. , Dec. 22, 2014 /PRNewswire/ ... today announced that it has signed a letter ... company that has developed and patented a nanotechnology-based ... medical diagnostics products that enable rapid on-site collection ... alcohol use/abuse and health issues in an immediate, ...
Breaking Biology Technology:Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3ALNE Announces Intention To Acquire BioTechPharma 2
... call and webcast to begin after markets close at 2:00 p.m. PT ... ... Masimo Corporation,(Nasdaq: MASI ), the inventor of Pulse CO-Oximetry and,Measure-Through-Motion- ... the period ended,September 27, 2008 after the market closes on Monday, October ...
... Oct. 15 PURE Bioscience (Nasdaq:,PURE), creators of ... revenues for the fiscal year ended July 31, ... with $336,400 in the,prior fiscal year. The Company ... or $(0.24) per share, compared with a loss ...
... Agency Expanding Industry Connections, MOUNTAINSIDE, N.J., Oct. ... medical education company,today announced the hiring of Todd ... leverage his experience in medical education and,publishing as ... L&M, he,served as Manager of Publication Sales at ...
Cached Biology Technology:Masimo to Report Third Quarter 2008 Financial Results on October 27, 2008 2PURE Bioscience Reports Fourth Quarter and Year End Results 2PURE Bioscience Reports Fourth Quarter and Year End Results 3PURE Bioscience Reports Fourth Quarter and Year End Results 4PURE Bioscience Reports Fourth Quarter and Year End Results 5PURE Bioscience Reports Fourth Quarter and Year End Results 6PURE Bioscience Reports Fourth Quarter and Year End Results 7L&M Healthcare Communications LLC Expands Client Services With Executive Team Expansion 2
Anti-Mouse D011.10 TCR, Biotin (Clone KJ1-26) (mouse IgG2a)...
Mouse monoclonal [050-04] to C2 ( Abpromise for all tested applications). entrezGeneID: 717 SwissProtID: P06681...
C/EBPalpha Antibody Shipping Temperature: Cold Storage Temperature: -20C...
...
Biology Products: